Soc. Generale Knock-Out SNW/ DE000CL7G2X2 /
2024-05-16 8:19:33 AM | Chg.-0.13 | Bid10:00:42 PM | Ask10:00:42 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.41EUR | -8.44% | - Bid Size: - |
- Ask Size: - |
SANOFI SA INHABER ... | 76.5504 - | 2078-12-31 | Call |
GlobeNewswire
05-16
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients wit...
GlobeNewswire
05-13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
05-13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
05-13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
05-08
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-07
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
05-02
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire
04-25
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire
04-23
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia